Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis

W.H. Bos; G.M. Bartelds; M. Vis; A. Horst; G. Wolbink; R.J. van de Stadt; D. van Schaardenburg; B.A.C. Dijkmans; W.F. Lems; M.T. Nurmohamed; L. Aarden; D. Hamann

doi:10.1136/ard.2008.088401

Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis

W.H. Bos, G.M. Bartelds, M. Vis, A. Horst, G. Wolbink, R.J. van de Stadt, D. van Schaardenburg, B.A.C. Dijkmans, W.F. Lems, M.T. Nurmohamed, L. Aarden, D. Hamann

Rheumatology

Research output: Contribution to journal › Article › Academic › peer-review

92 Downloads (Pure)

Abstract

Objective: To investigate the dynamics of IgG1 and IgG4 anti-citrullinated protein antibody ( ACPA) subclasses during anti-tumour necrosis factor (TNF) treatment in patients with rheumatoid arthritis ( RA). Methods: IgG, IgG1 and IgG4 ACPA levels were determined by ELISA on anti-citrullinated fibrinogen (ACF) and IgG1 : IgG4 ACPA ratios were calculated. A pilot study was performed in 28 ACF-positive patients treated with infliximab for one year. Confirmation of the results was obtained using a cohort of 180 consecutive patients treated with adalimumab for 28 weeks. Results: The median reduction in ACF levels was 31% for total IgG, 29% for IgG1, 40% for IgG4 and 22% for the IgG4 : IgG1 ACF ratio in the infliximab cohort. In adalimumab-treated patients, ACF levels declined 14% for total IgG and IgG1, and 36% for IgG4 ACF; the IgG4 : IgG1 ratio was reduced by 24% ( all percentage values p

Original language	English
Pages (from-to)	558-563
Number of pages	6
Journal	Annals of the Rheumatic Diseases
Volume	68
Issue number	4
DOIs	https://doi.org/10.1136/ard.2008.088401
Publication status	Published - 2009

Access to Document

10.1136/ard.2008.088401

237208Final published version, 248 KB

Cite this

Bos, W. H., Bartelds, G. M., Vis, M., Horst, A., Wolbink, G., van de Stadt, R. J., van Schaardenburg, D., Dijkmans, B. A. C., Lems, W. F., Nurmohamed, M. T., Aarden, L., & Hamann, D. (2009). Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 68(4), 558-563. https://doi.org/10.1136/ard.2008.088401

@article{3861fddfafad4afeb9413b8d61c7ff06,

title = "Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis",

abstract = "Objective: To investigate the dynamics of IgG1 and IgG4 anti-citrullinated protein antibody ( ACPA) subclasses during anti-tumour necrosis factor (TNF) treatment in patients with rheumatoid arthritis ( RA). Methods: IgG, IgG1 and IgG4 ACPA levels were determined by ELISA on anti-citrullinated fibrinogen (ACF) and IgG1 : IgG4 ACPA ratios were calculated. A pilot study was performed in 28 ACF-positive patients treated with infliximab for one year. Confirmation of the results was obtained using a cohort of 180 consecutive patients treated with adalimumab for 28 weeks. Results: The median reduction in ACF levels was 31% for total IgG, 29% for IgG1, 40% for IgG4 and 22% for the IgG4 : IgG1 ACF ratio in the infliximab cohort. In adalimumab-treated patients, ACF levels declined 14% for total IgG and IgG1, and 36% for IgG4 ACF; the IgG4 : IgG1 ratio was reduced by 24% ( all percentage values p",

author = "W.H. Bos and G.M. Bartelds and M. Vis and A. Horst and G. Wolbink and {van de Stadt}, R.J. and {van Schaardenburg}, D. and B.A.C. Dijkmans and W.F. Lems and M.T. Nurmohamed and L. Aarden and D. Hamann",

year = "2009",

doi = "10.1136/ard.2008.088401",

language = "English",

volume = "68",

pages = "558--563",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "4",

}

Bos, WH, Bartelds, GM, Vis, M, Horst, A, Wolbink, G, van de Stadt, RJ, van Schaardenburg, D , Dijkmans, BAC , Lems, WF , Nurmohamed, MT, Aarden, L & Hamann, D 2009, 'Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis', Annals of the Rheumatic Diseases, vol. 68, no. 4, pp. 558-563. https://doi.org/10.1136/ard.2008.088401

TY - JOUR

T1 - Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis

AU - Bos, W.H.

AU - Bartelds, G.M.

AU - Vis, M.

AU - Horst, A.

AU - Wolbink, G.

AU - van de Stadt, R.J.

AU - van Schaardenburg, D.

AU - Dijkmans, B.A.C.

AU - Lems, W.F.

AU - Nurmohamed, M.T.

AU - Aarden, L.

AU - Hamann, D.

PY - 2009

Y1 - 2009

N2 - Objective: To investigate the dynamics of IgG1 and IgG4 anti-citrullinated protein antibody ( ACPA) subclasses during anti-tumour necrosis factor (TNF) treatment in patients with rheumatoid arthritis ( RA). Methods: IgG, IgG1 and IgG4 ACPA levels were determined by ELISA on anti-citrullinated fibrinogen (ACF) and IgG1 : IgG4 ACPA ratios were calculated. A pilot study was performed in 28 ACF-positive patients treated with infliximab for one year. Confirmation of the results was obtained using a cohort of 180 consecutive patients treated with adalimumab for 28 weeks. Results: The median reduction in ACF levels was 31% for total IgG, 29% for IgG1, 40% for IgG4 and 22% for the IgG4 : IgG1 ACF ratio in the infliximab cohort. In adalimumab-treated patients, ACF levels declined 14% for total IgG and IgG1, and 36% for IgG4 ACF; the IgG4 : IgG1 ratio was reduced by 24% ( all percentage values p

AB - Objective: To investigate the dynamics of IgG1 and IgG4 anti-citrullinated protein antibody ( ACPA) subclasses during anti-tumour necrosis factor (TNF) treatment in patients with rheumatoid arthritis ( RA). Methods: IgG, IgG1 and IgG4 ACPA levels were determined by ELISA on anti-citrullinated fibrinogen (ACF) and IgG1 : IgG4 ACPA ratios were calculated. A pilot study was performed in 28 ACF-positive patients treated with infliximab for one year. Confirmation of the results was obtained using a cohort of 180 consecutive patients treated with adalimumab for 28 weeks. Results: The median reduction in ACF levels was 31% for total IgG, 29% for IgG1, 40% for IgG4 and 22% for the IgG4 : IgG1 ACF ratio in the infliximab cohort. In adalimumab-treated patients, ACF levels declined 14% for total IgG and IgG1, and 36% for IgG4 ACF; the IgG4 : IgG1 ratio was reduced by 24% ( all percentage values p

U2 - 10.1136/ard.2008.088401

DO - 10.1136/ard.2008.088401

M3 - Article

C2 - 18445623

VL - 68

SP - 558

EP - 563

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 4

ER -